Background: Gami-hyunggyeyeongyotang (GMHGYGT) is a polyherbal medicine derived from an oriental prescription traditionally used in the treatment of allergic diseases such as allergic rhinitis (AR). This study aimed to evaluate the effects of GMHGYGT on ovalbumin (OVA) sensitization/challenge-induced AR in BALB/C mice, through examination of allergic inflammatory response regulation, as well as examination of human mast cells (HMC-1). Methods: Nasal symptoms were evaluated in the OVA-induced allergic rhinitis mouse model, and total immunoglobulin (Ig)E and OVA-specific IgE levels in serum were investigated. Eosinophil infiltration and thickness of the nasal mucosa, and levels of interleukin (IL)-1b and caspase-1 were also measured by immunohistochemistry. Additionally, the effect of GMHGYGT on the phorbol-12-myristate-13-acetate plus calcium ionophore A23187-induced phosphorylation of extracellular signal-regulated kinase, C-Jun N-terminal kinase and p38 in HMC-1 cells was investigated.
Introduction
Allergic rhinitis (AR) is an inflammatory disease of the nasal mucosa. 1, 2 It induces an immunoglobulin (Ig)E-mediated reaction resulting from inflammation of the airway mucosa with hypersensitivity caused by seasonal or perennial responses to specific allergens. 3, 4 Approximately 500 million people are affected by AR around the world, and it presents with symptoms of sneezing, itching, and respiratory obstruction causing pain. 1, 5 Besides these symptoms, AR can also lead to other inflammatory diseases such as asthma, rhinosinusitis, allergic conjunctivitis, otitis media with effusion, nasal polyp, tubal dysfunction, and adenoid hypertrophy.
beginning of the AR reaction, mast cells combine with immunoglobulin (Ig)E receptors on the basophil surface, which can trigger the release of inflammatory cytokines and histamine. 9 These steps contribute to increasing the recruitment of inflammatory cells and eosinophil migration to affected tissue. 10 Even though there are multiple treatments available for AR such as medical treatment, immunotherapy, or surgery, the rates of side effects and recurrence are high after stopping medication. 11 Therefore, alternative treatments with improved drug stability are needed. 12 Herbal medicines have been used for the traditional treatment of various allergic diseases to maintain immune balance. Hence, many studies aiming to find an appropriate treatment for AR have focused on traditional medicines, which have fewer side effects and are more stable than the currently used drugs. 13 Gami-hyunggyeyeongyotang (GMHGYGT) is a polyherbal medicine derived from the Chinese traditional prescription hyunggyeyeongyotang (HGYGT) for the treatment of runny nose, sneezing, and congestion.
14 Some experimental studies have reported that HGYGT and GMHGYGT had effects on fever, pain, and edema. 15 Previous reports also indicated that HGYGT has anti-allergy and anti-inflammatory effects, as well as experimental effects on histamines and serotonin. 16 However, the anti-allergy effect and mechanism of GMHGYGT remain unknown. The present study aimed to evaluate the effect of GMHGYGT on ovalbumin (OVA) sensitization/challenge-induced AR in BALB/C mice through regulation of the allergic inflammatory response. Nasal symptoms were evaluated in an OVA-induced allergic rhinitis mouse model. Cytokine, total IgE, and OVA-specific IgE levels in the serum were investigated to verify the effects of GMHYGYT. Eosinophil infiltration and thickness of the nasal mucosa, and levels of interleukin (IL)-1b and caspase-1 were also measured via immunohistochemistry. To provide more evidence for verification of the anti-AR mechanism, mitogenactivated protein kinases (MAPKs), nuclear factor (NF)-kB, and inhibitor of NF-kB (IkB-a) were examined through western blotting in HMC-1 cells in vitro.
Methods

Reagents
Phorbol 12-myristate 13-acetate (PMA) and calcium ionophore A23187 were purchased from SigmaeAldrich (St. Louis, MO, USA). Aqueous nonradioactive cell proliferation assay from Promega Corporation (Madison, WI, USA), Iscove's Modified Dulbecco's Medium and fetal bovine serum from Gibco BRL (Grand Island, NY, USA), and streptomycin from Invitrogen (Carlsbad, CA, USA). Antibodies to phosphorylated extracellular signal-regulated kinase (ERK), ERK, phosphorylated p38, p38, phosphorylated C-Jun N-terminal kinase (JNK) and JNK were purchased from Cell Signaling Technology (Danvers, MA, USA), to NF-kB, IkB-a, Lamin B, and actin from Santa Cruz Biotechnology (Santa Cruz, CA, USA), peroxidase IgG from Jackson ImmunoResearch (West Grove, PA, USA), and to caspase-1 and IL-1b from Santa Cruz Biotechnology. Chemical reagents diaminobenzidine tetrachloride, NiCl 2 $H 2 O, Triton™ X-100, and methyl Green were obtained from SigmaeAldrich.
Preparation of GMHGYGT
Herbal components of GMHGYGT were purchased from Omni Herb Inc. (Andong-si, Gyeongbuk, Korea). The substances and composition of GMHGYGT are presented in Table  1 . All herbs were authenticated by Professor Youngmin Bu, a medical botanist in the Department of Herbology, College of Korean Medicine, Kyung Hee University, Seoul, Korea; additionally, voucher specimens were preserved at Kyung Hee University. Herbs used in GMHGYGT were mixed according to the ratios listed in Table 1 . Dried GMHGYGT was extracted as follows. Mixed GMHGYGT (208 g) was boiled in 2.1 L distilled water (95e100 C) for 2 hours, and filtered using Whatman filter paper No. 3 (Maidstone, Kent, UK). The filtered extract was concentrated in a rotary vacuum evaporator then lyophilized to yield 34 g of dried powder (yield ratio 15.4%). The product was maintained at a temperature of À20 C until use. The chromatogram patterns of high-performance liquid chromatography (HPLC) was shown in Fig. S1 .
Animals
Six-week-old female BALB/c mice were purchased from Nara Biotech (Gangnam-gu, Seoul, Korea). All animal experiments were approved according to guidelines of the Kyung Hee University Institutional Animal Care and Use Committee (KHUASP(SE)-13-006). The mice were housed under controlled temperature (23 ± 3 C) with a relative humidity of 40e60% and 12 hour light/dark cycles. Food and water were provided ad libitum.
Elicitation and group classification of AR model
The 6-week-old female BALB/C mice were divided into four groups (n ¼ 8 per group): (1) control group; (2) OVA sensitized (OVA) group; (3) GMHGYGT group; and (4) cetirizine-treated (Cet) group. After the mice were stabilized for 1 week, they were OVA-sensitized by intraperitoneal injection of 50 mg OVA (chicken egg albumin; Sigma) in 200 mL of phosphate-buffered saline (PBS) containing 2 mg aluminum hydroxide (Alum; Sigma) on Day 0, Day 7, and Day 14. One week after the last injection on Day 21, the mice were challenged with 20 mL PBS containing 50 mg/mL OVA into the bilateral nasal cavities. From Day 21 to Day 31, mice in the Control and OVA groups were given saline by peroral administration, and those in the Cet group received 10 mg/kg cetirizine hydrochloride (Allertec Tab; Korean Drug, Seoul, Korea), and the GMHGYGT group was orally administered 134 mg/kg GMHGYGT 1 hour before intranasal challenge of OVA under the same conditions. Cetirizine, a secondgeneration antihistamine, is a major metabolite of hydroxyzine and a racemic selective H1 receptor inverse agonist used in the treatment of allergies, angioedema, and urticaria. 17 In this study, cetirizine was used as a positive control.
Nasal symptom evaluation
The mice (6 weeks old, female) were administrated OVA intranasally, and the nasal symptoms were evaluated 2 minutes later by counting the time of nasal rubbing and number of sneezing events for 10 minutes. This procedure was carried out for 10 days starting from Day 21 (Fig. S2 ). Three hours after the last observation, the mice were anesthetized with sodium pentobarbital. The blood was then collected via cardiac puncture, and the nasal mucosa and tissue were taken and stored at À20 C until use.
Measurement of total IgE and OVA-specific IgE in serum
Blood of the mice from each experimental group was collected via cardiac puncture. The blood was centrifuged to obtain serum, from which the total IgE and OVA-specific IgE were quantified using an enzyme-linked immunosorbent assay (ELISA).
Measurement of cytokines in the serum
To demonstrate the effect of GMHGYGT on allergic responses in the AR model, the levels of IL-5, IL-6, IL-1b, monocyte chemoattractant protein (MCP)-1, and macrophage inflammatory protein (MIP)-2 were measured using a mouse cytokine/chemokine magnetic bead panel kit (EMD Millipore, Billerica, MA, USA). The plate was washed with 200 mL wash buffer for 10 minutes at room temperature, and then 25 mL standard solution and assay buffer were added to the appropriate wells. The standard serum matrix solution (25 mL) was added to the background well. Diluted serum was mixed with assay buffer, and 25 mL of beads was added to all wells. The plate was then covered by foil, and placed at room temperature for 20 minutes. Next, 25 mL of detection antibody was added to the wells and reacted for 1 hour at room temperature, after which streptavidinephycoerythrin were added to each well and mixed for 30 minutes. After washing twice, 150 mL sheath fluid was added to the wells and mixed for 5 minutes. The plate was measured with the Luminex 200 System (Luminex, Austin, TX, USA).
Histological evaluation
The heads of the mice were fixed using 10% formalin, then the nasal tissue was separated from the muscle and skin of the head. Nasal tissue was decalcified in 10% EDTA buffer for 14 days. The tissue was embedded in paraffin and sectioned to 5 mm, and the slides were stained with hematoxylin and eosin. The infiltration of eosinophils and thickness of the nasal mucosa were observed.
Immunohistochemical staining
AR tissue was tested by immunohistochemical staining. AR tissue sections were washed three times with PBS for 5 minutes, then reacted with 0.3% H 2 O 2 for 10 minutes. Tissue was reacted for 1 hour in blocking solution, which was a mixture of PBS with 10% normal serum (Jackson Immuno Research). The tissue was then washed three times, and treated with primary antibody overnight at 4 C. Caspase-1 and IL-1b (Santa Cruz Biotechnology) were used as the primary antibodies in a solution with a mixture of bovine serum albumin (GenDepot, Katy, TX, USA) and Triton X-100 with PBS. After reaction, the tissue was incubated with peroxidase IgG for 1 hour. It was then reacted with diaminobenzidine tetrachloride (Sigma) mixed with NiCl 2 $H 2 O (Sigma). Finally, the tissue was stained with Methyl Green as a counter stain.
HMC-1 cell culture
HMC-1 cells were provided by Prof. H.M. Kim (Department of Pharmacology, Kyung Hee University). The HMC-1 cell line is useful for studying cytokine activation pathways in immediate allergic reactions. 18, 19 HMC-1 cells were incubated in Iscove's Modified Dulbecco's Medium with 100 U/mL penicillin, 100 mg/mL streptomycin, and 10% heat-inactivated fetal bovine serum at 37 C, 5% CO 2 , and 95% humidity.
MTS assay for cell viability
Cell viability was tested by the MTS colorimetric assay. MTS assay is using conversion of the tetrazolium salt into a colored aqueous soluble formazan, produced by mitochondrial activity of viable cells. HMC-1 cells (1 Â 10 5 ) were plated in 96-well plates with various GMHGYGT concentrations (0.1 mg/mL, 1 mg/mL, 10 mg/mL, 50 mg/mL, and 100 mg/mL), and the cells were incubated for 24 hours in a 37 C incubator. MTS solution (2 mg/mL) was added to each well, and the cells were placed in an incubator for an additional 2 hours at 37 C. The optical density of the 96-well culture plates was measured at 490 nm with an ELISA reader. The formazan optical density of the untreated control cells was deemed to represent 100% viability.
Western blot analysis
HMC-1 cells (5 Â 10 6 ) were treated with various GMHGYGT concentrations (1 mg/mL, 10 mg/mL, and 100 mg/ mL) for 1 hour, stimulated with PMA and A23187, and incubated for an additional 2 hours for nuclear proteins, and 30 minutes for MAPKs. Western blot analysis was performed on the cell extracts. Harvested cells were treated by a detergent lysis procedure using lysis buffer to obtain the cell extract [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), KCl, MgCl 2 , dithiothreitol, phenylmethanesulfonyl fluoride, NaCl glycerol, EDTA]. Samples were heated at 95 C for 5 minutes and centrifuged. Proteins were then resolved by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, then electrotransferred to nitrocellulose membranes. The membrane were blocked for 1 hour with 1 L phosphate-buffered saline (PBS) with 0.1% Tween 20 (PBST) containing 5% skimmed milk, and then incubated with primary antibodies overnight at 4 C. Blots were incubated with peroxidaseconjugated secondary antibodies at room temperature, and the antibody-specific proteins were visualized by an enhanced chemiluminescence procedure, using an enhanced chemiluminescence detection reagent (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Statistical analysis
The data of symptom scores, eosinophil infiltration in nasal mucosa, expression of caspase-1 and IL-1b were analyzed by use of nonparametric KruskaleWallis analysis of variance and ManneWhitney U test. The data of IgE level, proinflammatory cytokines and in vitro assay were analyzed for statistical significance by one-way analysis of variance, followed by Dunnett's multiple comparison test. Statistical analysis was presented using the GraphPad PRISM Software (Graphpad Software Inc., La Jolla, CA, USA). Data were presented as mean ± standard error of the mean, and p < 0.05 was considered to be significant.
Results
Effects of GMHGYGT on behavior in rhinitis mouse model
From Day 21, the frequency of rubbing was measured in the OVA-induced rhinitis model. The result indicated that there were 150 ± 5.79 events in the OVA group; a significant increase from the 100.4 ± 7.22 events observed in the Control group. The rubbing value of the Cet group was 55.8 ± 6.13, while that of the GMHGYGT group was 76.6 ± 6.31. The GMHGYGT group demonstrated a significant decrease compare with the OVA group (Fig. 1A and B) .
The number of sneezing events was counted for 10 days. In the Control group, 31.4 ± 4.08 events occurred, while 88.2 ± 9.05 were observed in the OVA group. Again, the number in the OVA group was significantly higher than in the Control group. The number of sneezes was only 16.4 ± 0.94 in the Cet group and 25.8 ± 3.61 in the GMHGYGT group; also representing significant decreases compared to the OVA group ( Fig. 1C and D) .
As a preliminary study to determine the most effective dose of GMHGYGT on the OVA-induced AR murine model, we tested the inhibitory effect of GMHGYGT in two doses (13.4 mg/kg and 134 mg/kg). The number of sneezing or nasal rubbing events was reduced by GMHGYGT treatment in a dose-dependent manner (Fig. S3 ).
Effect of GMHGYGT on IgE and OVA-specific IgE levels in serum of the AR model
The total serum IgE level of the OVA group (2652.3 ± 154.6 ng/ml) was higher than in the Control group (1076.5 ± 144.4 ng/ ml). The group administered cetirizine showed a significant decreased compared to the OVA group. IgE production was inhibited in the GMHGYGT group (2341.7 ± 160.7 ng/ml; Fig. 2A ). The serum OVA-specific IgE level was 12.10 ± 1.46 Unit/ml in the OVA group, which was significantly higher than in the Control group (4.84 ± 0.83 Unit/ml). The serum IgE level in the Cet group (7.11 ± 0.14 Unit/ml) and GMHGYGT group (7.38 ± 1.16 Unit/ml) both decreased significantly compared with the OVA group (Fig. 2B ).
Effect of GMHGYGT on cytokine and chemokine in serum of AR model
The serum concentrations of IL-5, IL-6, IL-1b, MCP-1, and MIP-2 in the OVA group were also significantly higher than the Control group (Table 2) . IL-5, IL-6, IL-1b, MCP-1, and MIP-2 levels of the GMHGYGT group were significantly reduced compared with the OVA group. For the Cet group, only the levels of MCP-1 and MIP-2 were significantly lower than in the OVA group. 
Histological changes of the nasal mucosa and infiltration of eosinophils
The number of infiltrated eosinophils in the OVA group was significantly higher than in the Control group. Regarding the Cet and GMHGYGT groups, the numbers were significantly reduced compared with the OVA group (Fig. 3A and  B) . The nasal mucosa thickness of the OVA group was 17.8 ± 2.7 mm; also demonstrating a significant increase compared with the Control group (10.8 ± 1.3 mm) . The Cet group demonstrated a thickness of 10.8 ± 1.5 mm, while the GMHGYGT group had a thickness of 9.8 ± 1.8 mm. Both groups showed significantly decreased nasal mucosa thickness (Fig. 3A and C) .
Immunohistochemistry of nasal mucosa and expression of caspase-1 and IL-1b
Immunohistochemistry was performed to measure the levels of caspase-1 and IL-1b expression in the OVA-induced AR mouse model. Caspase-1 expression in the nasal septum of the GMHGYGT group was significantly lower than in the OVA group (Fig. 4) , while the decrease in IL-1b expression was not significant.
Effect of GMHGYGT on PMA plus A23187-stimulated MAPK activation
To measure the MAPKs of mast cells treated with GMHGYGT, western blotting was performed using HMC-1 cells. Phosphorylated-ERK and phosphorylated-JNK were inhibited Fig. 3 . Histological changes of nasal mucosa and infiltration of eosinophils (arrows) in the nasal mucosa of the allergic rhinitis model. (A) Thickness of the nasal septum in nasal mucosa (magnification: 40Â, 400Â, and 1000Â). Lane 3 marked eosinophil infiltration. Eosinophil infiltration to the nasal mucosa was determined by staining with Harris hematoxylin. OVA þ Cet and OVA þGMHGYGT groups were orally treated with cetirizine hydrochloride (10 mg/kg body weight) or GMHGYGT (134 mg/kg), respectively, 1 hour before intranasal challenge with OVA. Control and OVA groups were treated with distilled water. Columns and error bars represent the mean ± standard error. *p < 0.01, significantly different from the Control group. **p < 0.05 and ***p < 0.01, significantly different from the OVA group. Cet ¼ cetirizine; GMHGYGT ¼ Gami-hyunggyeyeongyotang; OVA ¼ ovalbumin.
by the GMHGYGT concentration of 100 mg/mL (Fig. 5) . In contrast, phosphorylated-p38 had no significant change.
Effect of GMHGYGT on PMA plus A23187-stimulated NF-kB activation and IkB-a degradation
To measure the NF-kB activation and IkB-a degradation in mast cells treated with GMHGYGT, western blotting was performed with HMC-1 cells. GMHGYGT inhibited the degradation of IkB-a in a concentration-dependent manner. GMHGYGT significantly decreased IkB-a degradation compared with the OVA group at a concentration of 100 mg/ mL. Moreover, GMHGYGT also demonstrated concentrationdependent inhibition of NF-kB, with significant reduction at a concentration of 100 mg/mL compared to the OVA group (Fig. 6 ).
Discussion
In the present study, the effect of GMHGYGT treatment on an OVA-induced AR mouse model was examined. GMHGYGT effectively ameliorated the allergic symptoms and suppressed the production of total and OVA-specific serum IgE. It also inhibited the expression of IL-5, IL-6, IL1b, MCP-1, and MIP-2 in serum of AR mice. In addition, suppression of the NF-kB signaling pathway was observed in HMC-1 cells treated with GMHGYGT.
The allergic inflammatory response is initiated within minutes of allergen exposure and is primarily due to the release of mediators by mast cells, including cytokines (IL-4, IL-5, and IL-6), chemotactic factors, and enzymes. 9 The net effect of these mediators is to produce the early symptoms of AR, and to stimulate the production and adhesion of circulating leukocytes, especially eosinophils, as well as their infiltration into the local tissue. 20 OVA sensitization and challenge in animal models leads to an increase in the OVA-specific IgE in plasma and infiltration of inflammatory cells in epithelium and subepithelium of the nasal mucosa. 21 In the present study, GMHGYGT remarkably inhibited the symptoms of rhinitis including the nasal rubbing time, number of sneezing events, and the increase in thickness of the nasal septum. In addition, the number of infiltrated eosinophils and the nasal mucosa thickness were significantly lower in the GMHGYGT group compared with the OVA group. These results demonstrated that GMHGYGT alleviated the allergic immune response in the AR model by reducing the infiltration of eosinophils.
Exposure to allergen initiates a cascade of biochemical and cellular events, resulting in the synthesis and release of IgE. This IgE-mediated response is marked by the T helper 2 immunological response, with mast cell and eosinophil expression. 20 In this study, GMHGYGT decreased the total IgE, with significant reduction of the OVA-specific IgE. This indicated that GMHGYGT inhibited the allergic response, especially through the reduction of OVA-specific IgE.
T helper 2 cells produce cytokines such as IL-5, IL-6, MCP, and MIP, which induce hypersensitivity of eosinophils and mast cells, and the production and differentiation of B lymphocytes. 22 IL-5 regulates the growth and differentiation of eosinophils, and serves as an essential signal for their movement into inflammatory tissue upon antigen exposure. 23 IL-6 has the important role of inducing cell generation, growth, survival, and migration during inflammatory reaction. 24 MCP and MIP are the key factors that affect the movement or activation of eosinophils and neutrophils. 25, 26 In this study, the GMHGYGT group appeared to have significant reduction in the serum levels of IL-5, IL-6, MCP-1, and MIP-2 compared to the OVAinduced group. These results suggest that GMHGYGT might influence the production of IL-5, IL-6, MCP-1, and MIP-2 during the process of antigen-specific IgE production.
The activation of caspase-1 can induce inflammation. Caspase-1 contains an N-terminal caspase recruitment domain that is capable of activating NF-kB associated with inflammatory responses. 27 Caspase-1 contributes to the activation of IL-1b by separating IL-1b from precursors. 28 IL-1b plays a role as a highly inflammatory cytokine, and is considered the host immune defensor. 29 In the present study, GMHGYGT considerably decreased the expression of caspase-1 and IL1b in the nasal mucosa tissue, as observed through immunohistochemistry analysis. These results suggest that GMHGYGT can attenuate allergic inflammation by suppressing the expression of IL-1b and caspase-1.
Mast cells are activated by the synthesis of cytokines that can damage the target inflammatory tissue. 9 In this study, the MAPKs cascade and NF-kB pathway were investigated via protein levels in HMC-1 cells. MAPKs including ERK, JNK, and p38 are responsible for various functions including the proliferation, differentiation, and apoptosis of cells, cellular response to cytokines and stress control. 30 ERK is essential for cell proliferation and differentiation in the signaling pathways. JNK and p38 are induced by environmental stresses and growth factors, and are known to promote cell growth inhibition, inflammatory response, and apoptosis. 31e33 In the present study, GMHGYGT inhibited expression of phosphorylated-ERK and phosphorylated-JNK. This means that GMHGYGT inhibited the inflammatory reaction in mast cells involved in the production of inflammatory cytokines through blocking the phosphorylation of ERK and JNK. In addition, GMHGYGT inhibited the phosphorylation of NFkB. These results indicate that GMHGYGT could regulate the expression of proinflammatory cytokines through the inactivation of phosphorylated-IkB and translocation of NF-kB into the nucleus.
In conclusion, our study demonstrated GMHGYGT to have an antiallergic effect by improving the symptoms of rhinitis, and inhibiting the release of allergic mediators in the OVAinduced AR model. In addition, GMHGYGT has antiinflammatory activity by suppressing the production of inflammatory cytokines such as IL-5, IL-6, IL-1b, MCP-1, and MIP-2, via the ERK, JNK, and NF-kB pathways in HMC-1 cells. These results suggest that GMHGYGT might be a good therapeutic drug for the treatment of allergic rhinitis.
